Monograph Details
|
|
Neoplasms
> Antimetabolites
|
|
Cytarabine |
| Manufacturer |
|
Bedford Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antimetabolite. |
| Generic Name |
|
Cytarabine 100mg, 500mg, 1g, 2g; per vial; lyophilized pwd for IV, intrathecal, SC inj after reconstitution. |
| Indications |
|
Remission induction in acute non-lymphocytic leukemia of adults and children. Acute lymphocytic leukemia. Chronic myelocytic leukemia (blast phase). Prophylaxis and treatment of meningeal leukemia (intrathecal route). |
| Adults and Children |
|
Induction therapy of acute non-lymphocytic leukemia: 100mg/m2 per day by continuous IV infusion (days 1–7) or 100mg/m2 IV every 12 hours (days 1–7). Acute lymphocytic leukemia and chronic myelocytic leukemia: see literature. Meningeal leukemia: Usual range: 5–75mg/m2 intrathecally; may give once daily for 4 days to once every 4 days; most frequently used dose: 30mg/m2 every 4 days until cerebrospinal fluid findings are normal. |
| Precautions |
|
Do not use diluent with benzyl alcohol for intrathecal administration. Pre-existing myelosuppression. Renal or hepatic impairment. Monitor blood counts, renal, hepatic function. Neonates. Pregnancy (Cat.D); avoid use. Nursing mothers. |
| Interactions |
|
May antagonize gentamicin, fluorocytosine. |
| Adverse Reactions |
|
Myelosuppression (leukopenia, thrombocytopenia, anemia), GI upset, anorexia, abdominal pain, oral ulceration, rash, fever, hepatic dysfunction, infection, bleeding; cytarabine syndrome, hyperuricemia, pancreatitis, paralysis (rare), others. |
| How Supplied |
Vials (100mg, 200mg)—10
1g, 2g—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
